Rona Therapeutics
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Tower 3 Jnb Life Science Park no.795 Kan...Website
www.ronatherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Rona Therapeutics
Rona Therapeutics is a world leading nucleic acid therapeutics company dedicated to addressing metabolic and degenerative diseases. Inceptioned in 2021, Rona Therapeutics has advanced several best-in-class siRNA therapeutics in the clinic or IND enabling stage, including PCSK9 siRNA for hypercholesteremia and APOC3 siRNA for mixed dyslipidemia. With longer duration, deep knockdown and improved tolerability, Rona Therapeutics metabolic assets have demonstrated differentiated profile to address unmet needs in cardiovascular diseases, MASH, obesity and renal diseases. Rona Therapeutics has built proprietary extrahepatic delivery platform in neuro degenerative diseases to fully exploit nucleic acid delivery potential beyond liver. With robust knockdown potency and long-term duration (Q9M or longer), multiple assets are progressing into IND enabling stage to treat complex diseases, i.e. ALS, Alzheimer's Diseases etc. that cannot be drugged with conventional modalities. The Company has raiseRead more
Rona Therapeutics Org Chart
GR
Operation Co-Founder & Vice President
JY
Vice President
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rona Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Rona Therapeutics has new funding data
Rona Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Rona Therapeutics
Click to see if Rona Therapeutics had a recent Job posting/layoffs
Earning: See what the market has to say on Rona Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Rona Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Rona Therapeutics launches new products
Check out if Rona Therapeutics is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Rona Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rona Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rona Therapeutics.
Rona Therapeutics financials insights
Gather financial insights about Rona Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$68M
Rona Therapeutics Tech Stack
A closer look at the technologies used by Rona Therapeutics
See more technologies
Most Recent Scoops
Project
Research & Development, Legal Affairs, Medical Research, Regulations
Project
A mid-level source in Information Security has indicated that the organization has completed initiatives related to asset management within the last nine months.
Asset Management, Information Security, Security
Project
A mid-level source in Information Security has indicated that the organization is planning to begin initiatives related to cloud orchestration within three months. Rona Therapeutics is currently evaluating Microsoft Azure Automation.
Cloud, Information Security, Automation, Security, Workforce Management
Pain Point
Project
A mid-level source in Information Security has indicated that the organization is planning to remediate challenges related to enterprise application integration (EAI).
Pain Point, Integration, Information Security, Enterprise Software, Security, Software, Enterprise Resource Planning
Pain Point
Project
Pain Point, Information Security, Enterprise Software, Security, Software, Enterprise Resource Planning
Rona Therapeutics News & Media
Rona Therapeutics Unveils the Global First Bi-valent PCSK9-LPA siRNA into Clinical Development for Cardiovascular Risk Reduction
SHANGHAI and SANTA BARBARA, Calif., Dec. 17, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in next-generation RNAi medicines, today announced the submission of RN5681 to the Australian Human Research Ethics Committee (HREC), advancing the company's first bi-valent siRNA into...Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE...Rona Therapeutics Advances INHBE siRNA Into Phase 1 Clinical Development
SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today announced the recent completion of Cohort 1 dosing in its Phase 1 first-in-human clinical study of RN3161, an investigational GalNAc-conjugated siRNA targeting INHBE...Rona Therapeutics Presents Phase 1 Data for RN0361, a Long-Acting APOC3-Targeting siRNA, at the American Heart Association 2025 Scientific Sessions
NEW ORLEANS, Nov. 10, 2025 /PRNewswire/ -- Rona Therapeutics, a global leader in developing next-generation RNAi therapeutics, presented highlights of Phase 1 clinical data for RN0361, a long-acting Apolipoprotein C3 (ApoC3) siRNA. RN0361 achieved potent, durable reductions in ApoC3 and triglycerides (TG) lasting at least six months in a single dose first-in-human trial, establishing a potential best-in-class profile to prevent pancreatitis in severe hypertriglyceridemia (HTG) and reduce cardiov
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Rona Therapeutics
Sign Up For FreeTo access detailed company insights
Rona Therapeutics is a world leading nucleic acid therapeutics company dedicated to addressing metabolic and degenerative diseases. Inceptioned in 2021, Rona Therapeutics has advanced several best-in-class siRNA therapeutics in the clinic or IND enabling stage, including PCSK9 siRNA for hypercholesteremia and APOC3 siRNA for mixed dyslipidemia. Wit... Read More
